Taiwan · Delayed Price · Currency is TWD AmCad BioMed Statistics
Total Valuation
AmCad BioMed has a market cap or net worth of TWD 924.66 million. The enterprise value is 668.62 million.
| Market Cap | 924.66M |
| Enterprise Value | 668.62M |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AmCad BioMed has 63.33 million shares outstanding. The number of shares has increased by 0.96% in one year.
| Current Share Class | 63.33M |
| Shares Outstanding | 63.33M |
| Shares Change (YoY) | +0.96% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.64% |
| Owned by Institutions (%) | 0.95% |
| Float | 31.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 32.33 |
| PB Ratio | 1.57 |
| P/TBV Ratio | 2.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 23.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.49, with a Debt / Equity ratio of 0.02.
| Current Ratio | 18.49 |
| Quick Ratio | 16.99 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.28 |
| Interest Coverage | -429.08 |
Financial Efficiency
Return on equity (ROE) is -11.18% and return on invested capital (ROIC) is -8.82%.
| Return on Equity (ROE) | -11.18% |
| Return on Assets (ROA) | -8.61% |
| Return on Invested Capital (ROIC) | -8.82% |
| Return on Capital Employed (ROCE) | -14.52% |
| Weighted Average Cost of Capital (WACC) | 5.83% |
| Revenue Per Employee | 841,265 |
| Profits Per Employee | -1.55M |
| Employee Count | 34 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.63 |
Taxes
In the past 12 months, AmCad BioMed has paid 12,000 in taxes.
| Income Tax | 12,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.04% in the last 52 weeks. The beta is 0.30, so AmCad BioMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -11.04% |
| 50-Day Moving Average | 10.34 |
| 200-Day Moving Average | 12.74 |
| Relative Strength Index (RSI) | 83.01 |
| Average Volume (20 Days) | 105,523 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AmCad BioMed had revenue of TWD 28.60 million and -52.66 million in losses. Loss per share was -0.83.
| Revenue | 28.60M |
| Gross Profit | 10.33M |
| Operating Income | -86.68M |
| Pretax Income | -67.46M |
| Net Income | -52.66M |
| EBITDA | -75.81M |
| EBIT | -86.68M |
| Loss Per Share | -0.83 |
Balance Sheet
The company has 341.88 million in cash and 13.35 million in debt, with a net cash position of 328.54 million or 5.19 per share.
| Cash & Cash Equivalents | 341.88M |
| Total Debt | 13.35M |
| Net Cash | 328.54M |
| Net Cash Per Share | 5.19 |
| Equity (Book Value) | 588.04M |
| Book Value Per Share | 8.14 |
| Working Capital | 357.26M |
Cash Flow
In the last 12 months, operating cash flow was -47.31 million and capital expenditures -120,000, giving a free cash flow of -47.43 million.
| Operating Cash Flow | -47.31M |
| Capital Expenditures | -120,000 |
| Depreciation & Amortization | 10.87M |
| Net Borrowing | -4.76M |
| Free Cash Flow | -47.43M |
| FCF Per Share | -0.75 |
Margins
Gross margin is 36.13%, with operating and profit margins of -303.03% and -184.10%.
| Gross Margin | 36.13% |
| Operating Margin | -303.03% |
| Pretax Margin | -235.84% |
| Profit Margin | -184.10% |
| EBITDA Margin | -265.04% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AmCad BioMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.96% |
| Shareholder Yield | -0.96% |
| Earnings Yield | -5.69% |
| FCF Yield | -5.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AmCad BioMed has an Altman Z-Score of 17.88 and a Piotroski F-Score of 1.
| Altman Z-Score | 17.88 |
| Piotroski F-Score | 1 |